Увійти

Готові списки джерел за темами / Systemic lupus erythematosus Immunological aspects / Статті в журналах

Статті в журналах з теми "Systemic lupus erythematosus Immunological aspects"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Systemic lupus erythematosus Immunological aspects.

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 12 лютого 2022

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Systemic lupus erythematosus Immunological aspects".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Kaleda, M. I., and I. P. Nikishina. "Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus." Rheumatology Science and Practice 58, no. 4 (September 4, 2020): 437–42. http://dx.doi.org/10.47360/1995-4484-2020-437-442.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Neuropsychiatric disorders in juvenile-onset systemic lupus erythematosus (SLE) stay in the focus of attention in recent decades due to significant influence of CNS lesions on SLE course in general, necessity to optimize therapeutic interventions and outline prognosis. This paper considers the prevalence of neurolupus in children and adolescents, specific features of the clinical picture, possible relationships with other SLE manifestations and immunological disorders, aspects of neuropsychiatric disorders pathogenesis and potential influence of growing and developing nervous system on SLE course, resulting in varying neurolupus manifestations and prognosis.

2

Farid, EmanM, AdlaB Hassan, AliA Abalkhail, AmgadE El-Agroudy, SameerAl-M. Arrayed, and SumayaM Al-Ghareeb. "Immunological aspects of biopsy-proven lupus nephritis in Bahraini patients with systemic lupus erythematosus." Saudi Journal of Kidney Diseases and Transplantation 24, no. 6 (2013): 1271. http://dx.doi.org/10.4103/1319-2442.121286.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Evangelopoulos, M. E., M. Alevizaki, S. Toumanidis, D. Sotou, C. D. Evangelopoulos, D. A. Koutras, S. F. Stamatelopoulos, and M. Mavrikakis. "Mitral valve prolapse in systemic lupus erythematosus patients: clinical and immunological aspects." Lupus 12, no. 4 (April 2003): 308–11. http://dx.doi.org/10.1191/0961203303lu314oa.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Aleksandrova, N. V., A. V. Aleksandrov, I. Yu Alekhina, and O. V. Paramonova. "CLINICAL AND IMMUNOLOGICAL ASPECTS OF CHRONIC HEADACHES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS." Medical academic journal 19, no. 1S (December 15, 2019): 54–56. http://dx.doi.org/10.17816/maj191s154-56.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: to study the clinical and immunologica features of the manifestation of chronic pain in systemic lupus erythematosus (SLE) patients with neurological symptoms.Methods. We examined 30 healthy individuals and 38 patients with SLE. Beck’s depression questionnaire was used to assess the presence of depressive symptoms. Antibodies to adenosine deaminase (anti-ADA), β2-glycoprotein-I-dependent antibodies to phospholipids of the IgG class (anti-FL) and antibodies to double-stranded DNA (anti-dsDNA) were determined in the serum of patients with SLE. Doppler sonography of the brachiocephalic arteries was performed for all patients with SLE.Results. Complaints about the presence of headaches of varying severity presented 35 people (92.1%). Migraine was recorded in 63.2% patients with SLE. Doppler ultrasound in patients with SLE with chronic headaches in 66.7% of cases showed signs of reduced blood flow in the arteries of the vertebrobasilar basin, which may indicate chronic brain ischemia. Signs of depressive disorder of varying severity were found in 36.8% of patients with SLE, and in patients with neurological disorders, moderate (p = 0.027) and severe (p = 0.041) depression were more often detected. Elevated levels of anti-ADA were found in 36.8%, and anti-FL in 44.7% of patients with SLE. It was noted that “migraine-like” manifestations of chronic pain syndrome were more common in the group of patients with SLE, who had a combined increase in anti-ADA and anti-FL (χ2 = 4.5; p = 0.024). Since a certain part of ADA is concentrated in the plasma membranes of vascular and platelet endothelium cells, it can be assumed that there is a conformational effect of anti-ADA on the β2-glycoprotein-I, leading to increased synthesis of anti-FL and undesirable activation of coagulation cascade in vessels.Conclusion. The combination of severe chronic headache with high levels of anti-ADA and anti-FL can precede the development of stroke and transient ischemic attacks, which emphasizes the need for additional immunological examination of patients with SLE with neurological symptoms.

5

Kini, Sandesh, Ramesh Bhat Y, Chennakeshava Thunga, Sowmya Shashidhara, and Akshatha Anand. "Clinical and Immunological Spectrum of Systemic Lupus Erythematosus in Children." Journal of Nepal Paediatric Society 40, no. 1 (August 10, 2020): 14–20. http://dx.doi.org/10.3126/jnps.v40i1.28460.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction: Systemic Lupus Erythematosus (SLE) is an auto immune disorder affecting mainly adolescent females and young women of reproductive age. The disease is characterised by widespread inflammation of blood vessels and connective tissues due to the presence of anti-nuclear antibodies (ANA). There are limited number of studies from South India on paediatric lupus. Our objectives were to study the clinical and immunological features of childhood SLE along with treatment modalities and its outcome at the end of one year follow up. The correlation between various auto-antibodies and systemic involvement was also assessed. Methods: This was a retrospective observational study carried out in paediatric unit at a tertiary care centre in South India. Data was obtained through patient’s medical records. From April 2003 to April 2019, 32 children were diagnosed to have SLE as per the American college of Rheumatology 1997 criteria. Results: The study population included 32 children fulfilling the criteria. Female to male ratio was 4.3:1. The mean age at diagnosis was 11.52 years. The most common clinical manifestations were renal (87.5%) followed by haematological (81.3%), musculoskeletal (59.4%), mucocutaneous (53.1%) and nervous system (31.3%) involvement. All patients were positive for anti-nuclear antibodies. Anti-double stranded DNA (78.1%) was the most common auto-antibody profile followed by anti-ribosomal p protein (37.5%) and anti-nucleosome antibody (37.5%). During the follow up, 13 (40.6%) children attained complete remission, 10 (31.2%) went into partial remission and nine (28.1%) had persisting active disease. Conclusion: The clinical spectrum and outcome of paediatric SLE depends upon the age of presentation and number of organ systems involved at the time of diagnosis. Our study throws light on various aspects of SLE in children from developing countries like India.

6

Han, Bobby Kwanghoon, Katherine D. Wysham, Kevin C. Cain, Helena Tyden, Anders A. Bengtsson, and Christian Lood. "Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus." Lupus Science & Medicine 7, no. 1 (May 2020): e000382. http://dx.doi.org/10.1136/lupus-2020-000382.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

ObjectiveNeutrophils contribute to the SLE pathogenesis. Neutrophil to lymphocyte ratio (NLR) is reported to correlate with disease activity in SLE. The aim of the study was to evaluate whether NLR reflects underlying immunopathogenic activity in SLE, as well as to determine the contribution of each component of NLR, neutrophil and lymphocyte count.MethodsData were obtained from a cohort of patients with SLE (n=141) recruited at Lund University, Sweden. NLR levels were compared between patients with SLE and healthy controls (n=79). The relationship between NLR and clinical and immunological markers was examined using Mann-Whitney U test and logistic regression analysis. High NLR was defined as above the 90th percentile of healthy individuals.ResultsPatients with SLE had elevated neutrophil count (p=0.04) and reduced lymphocyte count (p<0.0001), resulting in elevated NLR as compared with healthy controls (p<0.0001). Patients with high NLR had more active disease, and were more frequently on prednisone use and immunosuppressive medicines. High NLR was associated with immune complex (IC)-driven disease with presence of antidouble-stranded DNA antibodies (p=0.006), circulating ICs (p=0.02) and type I interferon (IFN) activity (p=0.009). Further, high NLR was associated with neutrophil abnormalities, including enrichment for low-density granulocytes (LDGs) (p=0.001), and increased levels of the serum neutrophil activation marker, calprotectin (p=0.02). Assessing the individual components within NLR, that is, neutrophil and lymphocyte count, high neutrophil count was associated with neutrophil activation markers (p<0.0001), whereas low lymphocyte count was associated with type I IFN activity and elevated numbers of LDGs (p=0.006 and p=0.001, respectively).ConclusionsNLR is elevated in patients with SLE as compared with healthy individuals, and is associated with key immunopathological events, including type I IFN activity and neutrophil activation. Neutrophil and lymphocyte count reflected different aspects of the pathogenesis of SLE. Further studies are needed to determine the causality of the associations.

7

Mak, Anselm. "The Impact of Vitamin D on the Immunopathophysiology, Disease Activity, and Extra-Musculoskeletal Manifestations of Systemic Lupus Erythematosus." International Journal of Molecular Sciences 19, no. 8 (August 10, 2018): 2355. http://dx.doi.org/10.3390/ijms19082355.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Over the past two decades it has been increasingly recognized that vitamin D, aside from its crucial involvement in calcium and phosphate homeostasis and the dynamics of the musculoskeletal system, exerts its influential impact on the immune system. The mechanistic roles that vitamin D plays regarding immune activation for combating infection, as well as pathologically and mediating autoimmune conditions, have been progressively unraveled. In vitro and in vivo models have demonstrated that the action of vitamin D on various immunocytes is not unidirectional. Rather, how vitamin D affects immunocyte functions depends on the context of the immune response, in the way that its suppressive or stimulatory action offers physiologically appropriate and immunologically advantageous outcomes. In this review, the relationship between various aspects of vitamin D, starting from its adequacy in circulation to its immunological functions, as well as its autoimmune conditions, in particular systemic lupus erythematosus (SLE), a prototype autoimmune condition characterized by immune-complex mediated inflammation, will be discussed. Concurring with other groups of investigators, our group found that vitamin D deficiency is highly prevalent in patients with SLE. Furthermore, the circulating vitamin D levels appear to be correlated with a higher disease activity of SLE as well as extra-musculoskeletal complications of SLE such as fatigue, cardiovascular risk, and cognitive impairment.

8

Rodríguez, Sandra, Andrés Muñoz, Rosa-Helena Bustos, and Diego Jaimes. "Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview." Biomedicines 8, no. 9 (August 23, 2020): 303. http://dx.doi.org/10.3390/biomedicines8090303.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1, and the modulation of cell-mediated immunity (B cells and T cells) by anti CD20 or anti CTAL-4 agents, and can increase the risk of associated infections or adverse events (AE). In this context, the entry of biotherapeutics represented a challenge for pharmacovigilance, risk management and approval by the main global regulatory agencies regarding biosimilars, where efficacy and safety are based on comparability exercises without being an exact copy in terms of molecular structure. The objective of this review is divided into three fundamental aspects: (i) to illustrate the evolution and focus of pharmacovigilance at the biopharmaceutical level, (ii) to describe the different approved recommendations of biopharmaceuticals (biological and biosimilars) and their use in rheumatic diseases (RDs) such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE) and other less frequent RD like cryopyrin-associated autoinflammatory syndromes (CAPS), and (iii) to identify the main AE reported in the post-marketing phase of RD biopharmaceuticals.

9

Balkrishna, Acharya, Pallavi Thakur, Shivam Singh, Swami Narsingh Chandra Dev, and Anurag Varshney. "Mechanistic Paradigms of Natural Plant Metabolites as Remedial Candidates for Systemic Lupus Erythromatosus." Cells 9, no. 4 (April 22, 2020): 1049. http://dx.doi.org/10.3390/cells9041049.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder involving a dysregulated immune response which ultimately leads to multiple organ failure. Several immunological and cellular checkpoints are available as drug targets. However, the available chemosynthetic drugs such as non-steroidal anti-inflammatory drugs and corticosteroids provide limited therapy with extreme toxicities. Moreover, the disease heterogeneity in SLE is very difficult to manage by a single drug component. Hence, it is imperative to utilize the holistic capabilities of natural plant products as immunomodulators and intracellular signaling regulators, thereby providing an auxiliary option of treatment. Additionally, the herbal drugs also serve as symptomatic relief providers, thereby serving as a prophylactic remedy in case of cerebrovascular, hepatic, nephropathological, hematological, cardiopulmonary, mucocutaneous and musculoskeletal manifestations of SLE. The present review attempts to showcase the current state of knowledge regarding the utility of plant-derived phyto-metabolites with their probable mechanistic roles in treating SLE, by means of targeting the signaling cascade, proinflammatory cytokine production and B–T cell co-stimulation. It is hoped that further preclinical and clinical studies will be embarked upon in order to understand the underlying therapeutic and mechanistic aspects of these medicinal herbs.

10

das Chagas Medeiros, M. M., M. Campos Bezerra, F. N. Holanda Ferreira Braga, M. R. Melo da Justa Feijão, A. C. Rodrigues Gois, V. C. do Rosário Rebouças, T. M. Amorim Zaranza de Carvalho, L. N. Solon Carvalho, and ÁT Mendes Ribeiro. "Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): comparison between childhood-onset, adult-onset, and late-onset SLE." Lupus 25, no. 4 (September 23, 2015): 355–63. http://dx.doi.org/10.1177/0961203315606983.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Todorovic-Djilas, Ljiljana, Tijana Icin, Jovanka Novakovic-Paro, and Ivana Bajkin. "Autoimmune thyroid disease and other non-endocrine autoimmune diseases." Medical review 64, no. 3-4 (2011): 183–87. http://dx.doi.org/10.2298/mpns1104183t.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction, Autoimmune diseases are chronic conditions initiated by the loss of immunological tolerance to self-antigens. They constitute heterogeneous group of disorders, in which multiple alterations in the immune system result in a spectrum of syndromes that either target specific organs or affect the body systematically. Recent epidemiological studies have shown a possible shift of one autoimmune disease to another or the fact that more than one autoimmune disease may coexist in a single patient or in the same family. Numerous autoimmune diseases have been shown to coexist frequently with thyroid autoimmune diseases. Autoimmune thyroid disease and other organ specific non-endocrine autoimmune diseases. This part of the study reviews the prevalence of autoimmune thyroid disease coexisting with: pernicious anaemia, vitiligo, celiac disease, autoimmune liver disease, miastenia gravis, alopecia areata and sclerosis multiplex, and several recommendations for screening have been given. Autoimmune thyroid disease and other organ non-specific non-endocrine autoimmune diseases. Special attention is given to the correlation between autoimmune thyroid disease and rheumatoid arthritis, systemic lupus erythematosus, syndrome Sj?gren, systemic sclerosis and mixed connective tissue disease. Conclusions. Screening for autoimmune thyroid diseases should be recommended in everyday clinical practice, in patients with primary organ-specific or organ non-specific autoimmune disease. Other?wise, in patients with primary thyroid autoimmune disease, there is no good reason of seeking for all other autoimmune diseases, although these patients have a greater risk of developing other autoimmune disease. Economic aspects of medicine require further analyzing of these data, from cost/benefit point of view to justified either mandatory screening or medical practitioner judgment.

12

RAMOS-CASALS, MANUEL, SANDRA MUÑOZ, FRANCISCO MEDINA, LUIS-JAVIER JARA, JOSÉ ROSAS, JAIME CALVO-ALEN, PILAR BRITO-ZERÓN, XAVIER FORNS, and JOSE-MARIA SÁNCHEZ-TAPIAS. "Systemic Autoimmune Diseases in Patients with Hepatitis C Virus Infection: Characterization of 1020 Cases (The HISPAMEC Registry)." Journal of Rheumatology 36, no. 7 (April 15, 2009): 1442–48. http://dx.doi.org/10.3899/jrheum.080874.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective.To describe the clinical and immunologic characteristics of a large series of patients with systemic autoimmune diseases (SAD) associated with chronic hepatitis C virus (HCV) infection.Methods.The HISPAMEC Registry is a multicenter international study group dedicated to collecting data on patients diagnosed with SAD with serological evidence of chronic HCV infection. The information sources are cases reported by physicians of the HISPAMEC Study Group and periodic surveillance of reported cases by a Medline search updated up to December 31, 2007.Results.One thousand twenty HCV patients with SAD were included in the registry. Patients were reported from Southern Europe (60%), North America (15%), Asia (14%), Northern Europe (9%), South America (1%), and Australia (1%). Countries reporting the most cases were Spain (236 cases), France (222 cases), Italy (144 cases), USA (120 cases), and Japan (95 cases). The most frequently reported SAD were Sjögren’s syndrome (SS; 483 cases), rheumatoid arthritis (RA; 150 cases), systemic lupus erythematosus (SLE; 129 cases), polyarteritis nodosa (78 cases), antiphospholipid syndrome (59 cases), inflammatory myopathies (39 cases), and sarcoidosis (28 cases). Twenty patients had 2 or more SAD. Epidemiological data were available in 677 cases. Four hundred eighty-seven (72%) patients were female and 186 (28%) male, with a mean age of 49.5 ± 1.0 years at SAD diagnosis and 50.5 ± 1.1 years at diagnosis of HCV infection. The main immunologic features were antinuclear antibody (ANA) in 61% of patients, rheumatoid factor (RF) in 57%, hypocomplementemia in 52%, and cryoglobulins in 52%. The main differential aspect between primary and HCV-related SAD was the predominance of cryoglobulinemic-related markers (cryoglobulins, RF, hypocomplementemia) over specific SAD-related markers (anti-ENA antibodies, anti-dsDNA, anti-cyclic citrullinated peptide) in patients with HCV.Conclusion.In the selected cohort, the SAD most commonly reported in association with chronic HCV infection were SS (nearly half the cases), RA and SLE. Nearly two thirds of SAD-HCV cases were reported from the Mediterranean area. In these patients, ANA, RF and cryoglobulins are the predominant immunological features.

13

Sebastiani, GD, and M. Galeazzi. "Immunogenetic studies on systemic lupus erythematosus." Lupus 18, no. 10 (August 11, 2009): 878–83. http://dx.doi.org/10.1177/0961203309106918.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Understanding the pathogenesis of systemic lupus erythematosus (SLE) remains a considerable challenge. Multiple abnormalities of both the innate and adaptive immune system have been described and, furthermore, immunological dysfunction precedes clinical presentation by many years. There is a strong genetic basis to SLE, which means that genetic studies can play a key role in furthering our understanding of this disease. Because susceptibility variants are present from birth and are unaffected by the course of the disease, or by its treatment, genetic analysis is, perhaps uniquely, capable of identifying fundamental, causative, disease mechanisms. In this article, we review our SLE immunogenetic studies performed in collaboration with the European Working Party on Systemic Lupus Erythematosus. By considering the results of our research and the recent advances obtained by genome-wide associations’ studies, we can begin to understand how dysregulation at a number of key immunological steps may predispose to the development of SLE.

14

Oktem, Ozgur, Hande Yagmur, Hale Bengisu, and Bulent Urman. "Reproductive aspects of systemic lupus erythematosus." Journal of Reproductive Immunology 117 (September 2016): 57–65. http://dx.doi.org/10.1016/j.jri.2016.07.001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Relle, Manfred, Bernd Foehr, and Andreas Schwarting. "Epigenetic Aspects of Systemic Lupus Erythematosus." Rheumatology and Therapy 2, no. 1 (June 2015): 33–46. http://dx.doi.org/10.1007/s40744-015-0014-y.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Qi, Yuan‐yuan, Xu‐jie Zhou, and Hong Zhang. "Autophagy and immunological aberrations in systemic lupus erythematosus." European Journal of Immunology 49, no. 4 (February 25, 2019): 523–33. http://dx.doi.org/10.1002/eji.201847679.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Pan, Lu, Mei-Ping Lu, Jing-Hua Wang, Meng Xu, and Si-Rui Yang. "Immunological pathogenesis and treatment of systemic lupus erythematosus." World Journal of Pediatrics 16, no. 1 (February 22, 2019): 19–30. http://dx.doi.org/10.1007/s12519-019-00229-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Pradhan, Vandana, M. Patwardhan, A. Rajadhyaksha, and K. Ghosh. "Clinical and immunological profile of systemic lupus erythematosus." Indian Pediatrics 50, no. 4 (April 2013): 405–7. http://dx.doi.org/10.1007/s13312-013-0115-z.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Yu, Haitao, Yasuo Nagafuchi, and Keishi Fujio. "Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus." Biomolecules 11, no. 7 (June 22, 2021): 928. http://dx.doi.org/10.3390/biom11070928.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Systemic lupus erythematosus (SLE) is characterized by immune system dysfunction and is clinically heterogeneous, exhibiting renal, dermatological, neuropsychiatric, and cardiovascular symptoms. Clinical and physiological assessment is usually inadequate for diagnosing and assessing pathophysiological processes in SLE. Clinical and immunological biomarkers could play a critical role in improving diagnosis, assessment, and ultimately, control of SLE. This article reviews clinical and immunological biomarkers that could diagnose and monitor disease activity in SLE, with and without organ-specific injury. In addition, novel SLE biomarkers that have been discovered through “omics” research are also reviewed.

20

Dupéré, Audrey, and Yves Poulin. "Facial Lipoatrophy following Systemic Lupus Erythematosus." Journal of Cutaneous Medicine and Surgery 7, no. 3 (May 2003): 232–35. http://dx.doi.org/10.1177/120347540300700308.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background: Acquired partial lipodystrophy is a rare disorder. An association with systemic lupus erythematosus has been reported. In these cases, an immunologic basis is suggested by the presence of C3 nephritic factor and hypocomplementemia. Objective: The following report presents the case of a woman who developed a rapid loss of facial subcutaneous fat a few months after complete spontaneous resolution of cutaneous lesions of lupus. Conclusion: Absence of C3NeF in this case suggests that other immunological factors may be involved in the pathogenesis.

21

Sy, Man Sun. "Systemic Lupus Erythematosus: Clinical and Experimental Aspects." Archives of Dermatology 124, no. 7 (July 1, 1988): 1136. http://dx.doi.org/10.1001/archderm.1988.01670070100036.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Theofilopoulos, A. N., R. Kofler, D. Noonan, P. Singer, and F. J. Dixon. "Molecular aspects of murine systemic lupus erythematosus." Springer Seminars in Immunopathology 9, no. 2-3 (October 1986): 121–42. http://dx.doi.org/10.1007/bf02099018.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Rastin, Maryam, Mahmoud Mahmoudi, Maryam Sahebari, and Nafiseh Tabasi. "Clinical & immunological characteristics in systemic lupus erythematosus patients." Indian Journal of Medical Research 146, no. 2 (2017): 224. http://dx.doi.org/10.4103/ijmr.ijmr_1356_15.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Font, J., R. Cervera, M. Navarro, L. Pallares, A. Lopez-Soto, J. Vivancos, and M. Ingelmo. "Systemic lupus erythematosus in men: clinical and immunological characteristics." Annals of the Rheumatic Diseases 51, no. 9 (September 1, 1992): 1050–52. http://dx.doi.org/10.1136/ard.51.9.1050.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Zharkova, Olga, Teja Celhar, Petra D. Cravens, Anne B. Satterthwaite, Anna-Marie Fairhurst, and Laurie S. Davis. "Pathways leading to an immunological disease: systemic lupus erythematosus." Rheumatology 56, suppl_1 (March 27, 2017): i55—i66. http://dx.doi.org/10.1093/rheumatology/kew427.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

SCALI, J. J., P. BARCENA, S. VISENTINI, J. SALOMON, and E. MORALES. "Hyperprolactinemia, Uveitis, and Systemic Lupus Erythematosus: Clinical-Immunological Correlation." Annals of the New York Academy of Sciences 876, no. 1 NEUROENDOCRIN (June 1999): 378–82. http://dx.doi.org/10.1111/j.1749-6632.1999.tb07660.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Lila, Viktoria A., and Vadim I. Mazurov. "Profile of immunological markers in skin biopsies from patients with probable and confirmed systemic lupus erythematosus." HERALD of North-Western State Medical University named after I.I. Mechnikov 13, no. 1 (June 8, 2021): 39–48. http://dx.doi.org/10.17816/mechnikov63358.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The purpose of this study was to determine the profile of immunoreactants deposited in intact skin biopsies from the patients with confirmed and probable systemic lupus erythematosus. The study involved 94 patients who, along with a standard clinical and laboratory examination, underwent a biopsy of clinically healthy skin in the deltoid muscle area (lupus band test). The nature and combination of immune deposits in the skin, the strength of immunofluorescence, and the location were evaluated. In the patients with significant systemic lupus erythematosus (n = 56), lupus band test was positive in 60.7 % of the cases and correlated with disease activity according to SLEDAI 2K (p = 0.001). At the same time, the skin biopsy often revealed the immunoreactant IgM (85.3 %), the degree of fluorescence of which had direct correlations with the increased level of antibodies to dsDNA (p 0.05). In the examined patients with probable systemic lupus erythematosus, positive lupus band test was detected in 47 % of cases, and IgM was detected in 72.2% of patients, which brought them closer to the group of patients with confirmed systemic lupus erythematosus. However, 33.3% of patients with probable systemic lupus erythematosus had isolated deposits of any one immunoreactant, while the association of immunoreactants (IgM+IgG) and (IgM+IgG+C3) characteristic of confirmed systemic lupus erythematosus occurred in only 27.7 and 5.5% of cases, respectively. It should be noted that the C1q immunoreactant was detected in the skin biopsies with both confirmed (38.2%) and probable systemic lupus erythematosus (39%). The data obtained suggest that lupus band test with the presence of a specific pattern of immunoreactants can be used as an additional diagnostic test for the diagnosis of systemic lupus erythematosus.

28

Gavva, T. N., A. A. Pecherskikh, D. E. Gogolev, L. V. Teplova, Yu S. Shklyaeva, and Ya G. Spiryakina. "Consultation with rheumatologist: debut of systemic lupus erythematosus." Medical alphabet 1, no. 11 (June 15, 2021): 55–59. http://dx.doi.org/10.33667/2078-5631-2021-11-55-59.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Systemic lupus erythematosus (SLE) is one of the most complex rheumatological diseases, occurring with a variety of clinical forms and manifestations. The debuts and variants of the course of SLE can vary significantly, so it is called ‘chameleon disease’ or ‘the great imitator of diseases’. In 2019, a group of experts from the European Anti-Rheumatic League and the American College of Rheumatology developed the latest criteria for the diagnosis of systemic lupus erythematosus. A prerequisite for the diagnosis is a positive antinuclear factor in combination with the seven clinical criteria for SLE (constitutional, hematological, neuropsychiatric, skin‑mucosal, polyserositis, renal) and the three immunological signs (antiphospholipid antibodies, levels of complement and its fractions, SLE‑specific autoantibodies) The article describes a case of systemic lupus erythematosus, diagnosed in a patient who was admitted to the hospital with a directional diagnosis of ‘fever of unknown origin’. The diagnosis of systemic lupus erythematosus was established on the basis of seven clinical criteria and two immunological diagnostic criteria.

29

Li, Philip Hei, and Chak-Sing Lau. "Efficacy and Safety of Vaccinations in Systemic Lupus Erythematosus." Journal of Clinical Rheumatology and Immunology 20, no. 01 (June 5, 2020): 35–41. http://dx.doi.org/10.1142/s2661341720300037.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Patients with rheumatological or immunological conditions, such as systemic lupus erythematosus (SLE), are particularly vulnerable to infections either due to the underlying immunological aberrations of the disease itself or treatment-related/iatrogenic immunosuppression. Infections remain the leading cause of morbidity and mortality in SLE patients and appropriate vaccination is of paramount importance. Despite clear guidance for the most common vaccinations, the greatest barrier to appropriate vaccinations likely remains with physician awareness or willingness for recommendation. To address this, we review the current evidence regarding the impact of the most commonly recommended vaccinations on SLE.

30

Mitic, Gorana. "Antiphospholipid syndrome accompanying systemic lupus erythematosus." Medical review 55, no. 3-4 (2002): 89–96. http://dx.doi.org/10.2298/mpns0204089m.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The aim of the study was the assessment of the prevalence of antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE). 72 patients with SLE had been investigated, 66 females and six males, aged 17 to 70 years, average 37,03. The presence of APA was determined using both ELISA assay for antiphospholipid antibodies ASSERACHROM APA by Diagnostica Stago and clotting tests for lupus anticoagulant: activated partial thromboplastin time (aPTT), tissue thromboplastin inhibition test (TTI) and dilute Russell viper venom time (dRVVT). Antiphospholipid antibodies have been found in 24 patients (33.44%), 10 of them were. with positive lupus anticoagulant tests, 6 of them were with positive ELISA test, while 8 of them had positive coagulation and immunological tests. Clinical manifestations that could be related to antiphospholipid syndrome were present in 22 patients (30.5%). The most common were thrombotic complications in 16 patients (22.25), recurrent spontaneous abortions in 7 patients (9.7%) and thrombocytopenia in 1 patient (1.39%). Presence of antiphospholipid syndrome was determined in 15 patients (20.83%). We can conclude that there is a significant correlation between presence of antiphospholipid antibodies and both thrombotic events and recurrent spontaneous abortions in SLE patients. Occurrence of thrombotic complications is in direct correlation with the level of antiphospholipid antibodies.

31

Adelowo, O. O., B. H. Olaosebikan, B. A. Animashaun, and R. O. Akintayo. "Juvenile systemic lupus erythematosus in Nigeria." Lupus 26, no. 3 (October 23, 2016): 329–33. http://dx.doi.org/10.1177/0961203316672927.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Juvenile systemic lupus erythematosus (JSLE) is a complex multisystemic autoimmune disorder of unknown cause. It accounts for about one in five cases of SLE. The tendency for SLE to run a fulminant course when it starts in childhood has made JSLE a potentially more severe disease than adult SLE. Reports of JSLE from sub-Saharan Africa are scanty in spite of the increasing reports of adult SLE. We conducted a 4-year retrospective study of JSLE cases seen at the Lagos State University Teaching Hospital between January 2010 and December 2014. Out of the 12 patients studied, eight were girls and four were boys. All patients had positive antinuclear antibody and extractable nuclear antibody tests. Anti-dsDNA antibody was positive in 10 patients. Eight patients had renal disease while four patients had neuropsychiatric manifestations. Haematological abnormalities and constitutional symptoms were present in all patients. Patients were treated with pulse methylprednisolone, oral prednisolone, hydroxychloroquine and azathioprine. Three patients also received rituximab. In conclusion, JSLE exists in Nigeria and exhibits clinical and immunological characteristics similar to its pattern in other parts of the world. It is, however, diagnosed late and is possibly being underdiagnosed as there is no paediatric rheumatologist in the country.

32

Levy, R. A., and J. F. de Carvalho. "Lupus and the brain: neuropsychiatric aspects in systemic lupus erythematosus." Lupus 26, no. 5 (April 2017): 451–52. http://dx.doi.org/10.1177/0961203317700487.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Niewold, Timothy B., Daniel N. Clark, Rafah Salloum, and Brian D. Poole. "Interferon Alpha in Systemic Lupus Erythematosus." Journal of Biomedicine and Biotechnology 2010 (2010): 1–8. http://dx.doi.org/10.1155/2010/948364.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The pleiotropic cytokine interferon alpha is involved in multiple aspects of lupus etiology and pathogenesis. Interferon alpha is important under normal circumstances for antiviral responses and immune activation. However, heightened levels of serum interferon alpha and expression of interferon response genes are common in lupus patients. Lupus-associated autoantibodies can drive the production of interferon alpha and heightened levels of interferon interfere with immune regulation. Several genes in the pathways leading to interferon production or signaling are associated with risk for lupus. Clinical and cellular manifestations of excess interferon alpha in lupus combined with the genetic risk factors associated with interferon make this cytokine a rare bridge between genetic risk and phenotypic effects. Interferon alpha influences the clinical picture of lupus and may represent a therapeutic target. This paper provides an overview of the cellular, genetic, and clinical aspects of interferon alpha in lupus.

34

Bhaskar, Lakkakula V. K. S., and Ganji Purnachandra Nagaraju. "Clinical and Immunogenetic Aspects of Systemic Lupus Erythematosus." Critical Reviews in Immunology 39, no. 5 (2019): 343–60. http://dx.doi.org/10.1615/critrevimmunol.2020033247.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

FROST, DeANNA BAKER. "Systemic Lupus Erythematosus — Basic, Applied, and Clinical Aspects." Journal of Rheumatology 43, no. 11 (November 2016): 2087. http://dx.doi.org/10.3899/jrheum.160771.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Emery, Helen. "Clinical Aspects of Systemic Lupus Erythematosus in Childhood." Pediatric Clinics of North America 33, no. 5 (October 1986): 1177–90. http://dx.doi.org/10.1016/s0031-3955(16)36114-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Rothfield, Naomi. "Clinical aspects and treatment of systemic lupus erythematosus." Current Opinion in Rheumatology 1, no. 3 (October 1989): 327–31. http://dx.doi.org/10.1097/00002281-198901030-00014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Justiz-Vaillant, Angel, Patrick E. Akpaka, and Peter Poonking. "Systemic Lupus Erythematosus: some Epidemiological and Clinical Aspects." American Journal of Public Health Research 3, no. 2 (February 26, 2015): 46–50. http://dx.doi.org/10.12691/ajphr-3-2-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Walsh, Stephen J., Charles Algert, and Naomi F. Rothfield. "Racial aspects of comorbidity in systemic lupus erythematosus." Arthritis Care & Research 9, no. 6 (December 1996): 509–16. http://dx.doi.org/10.1002/art.1790090613.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Andreoli, Laura, Francesca Crisafulli, and Angela Tincani. "Pregnancy and reproductive aspects of systemic lupus erythematosus." Current Opinion in Rheumatology 29, no. 5 (September 2017): 473–79. http://dx.doi.org/10.1097/bor.0000000000000415.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Jones, John Verrier. "Systemic lupus erythematosus: Clinical, pathological and therapeutic aspects." Transfusion Science 13, no. 2 (April 1992): 127–28. http://dx.doi.org/10.1016/0955-3886(92)90162-a.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

John, Kevin, Krupa Varughese, Ranil Johann Boaz, and Tarun George. "Lupus cystitis: unusual cause of renal failure in systemic lupus erythematosus." BMJ Case Reports 12, no. 12 (December 2019): e233446. http://dx.doi.org/10.1136/bcr-2019-233446.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

A 42-year-old woman presented with chronic fever, abdominal pain, intermittent loose stools and dysuria for 3 months. She had recently developed acute dyspnoea with acute kidney injury. She was found to have a contracted, thick-walled bladder with bilateral hydroureteronephrosis. She underwent bilateral percutaneous nephrostomies, following which her renal function recovered. She satisfied the clinical and immunological features of the Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus (SLE). She was initiated on immunosuppression. Lupus cystitis with a contracted bladder is an uncommon presentation of SLE.

43

Samundeswari, S., V. Ramalingam, and B. Latha. "Computer-Aided Diagnosis of Systemic Lupus Erythematosus Using Immunological Profile." Medico-Legal Update 18, no. 1 (2018): 525. http://dx.doi.org/10.5958/0974-1283.2018.00112.3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Font, J., L. Pallares, R. Cervera, A. Lopez-Soto, M. Navarro, X. Bosch, and M. Ingelmo. "Systemic lupus erythematosus in the elderly: clinical and immunological characteristics." Annals of the Rheumatic Diseases 50, no. 10 (October 1, 1991): 702–5. http://dx.doi.org/10.1136/ard.50.10.702.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Kadiyala, Ramya, Pushpa Gurudas Kini, Shrikiran Aroor, Sandeep Kumar, and Karen Moras. "Clinico-immunological profile and outcome of childhood systemic lupus erythematosus." Sri Lanka Journal of Child Health 48, no. 3 (September 5, 2019): 201. http://dx.doi.org/10.4038/sljch.v48i3.8753.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Sakkas, Lazaros I., Maria Boulbou, Despina Kyriakou, Irene Makri, Chrysanthi Sinani, Anastasios Germenis, and Nikolaos Stathakis. "Immunological features of visceral leishmaniasis may mimic systemic lupus erythematosus." Clinical Biochemistry 41, no. 1-2 (January 2008): 65–68. http://dx.doi.org/10.1016/j.clinbiochem.2007.10.008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Gamal, Sherif M., Samar M. Fawzy, Marwa Abdo, Fatema T. Elgengehy, Shada Ghoniem, and Alkhateeb Alkemry. "Immunological profile and dyslipidemia in Egyptian Systemic Lupus Erythematosus patients." Egyptian Rheumatologist 39, no. 2 (April 2017): 89–92. http://dx.doi.org/10.1016/j.ejr.2016.05.007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Tlish, M. M., Zhanna Y. Naatyzh, N. L. Sycheva, and T. G. Kuznetsova. "Systemic lupus erythematosus in the practice of dermatology." Clinical Medicine (Russian Journal) 96, no. 3 (July 20, 2018): 277–81. http://dx.doi.org/10.18821/0023-2149-2018-96-3-277-281.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Systemic lupus erythematosus (SLE) - an autoimmune disease of unknown etiology with multivariate manifestations, course and prognosis characterized by hyperproduction wide spectrum of organ autoantibodies and immune complexes that cause immunological damage to internal organs with the development of multiple organ failure Increased frequency of occurrence of the manifestations of autoimmune disease in dermatology practice, the complexity of creating diagnostic algorithms and untimely appointment of targeted erapii put this problem in a number of the most pressing. Skin rashes are often the leading symptom in the clinical picture of most cases of SLE. In the 20-33% of cases of SLE begins with cutaneous manifestations of the syndrome, with the result that patients are directed to the primary dermatological reception Submitted 3 clinical observation of patients with systemic lupus erythematosus, the diagnosis of which require a comprehensive survey to include histological examination of skin biopsies and immunological studies: blood analysis antinuclear factor on HEp-2 cells with determination of the type nucleus luminescence lupus anticoagulant in blood plasma, IgG antibodies to phospholipids and Ig class , Double-stranded DNA, antinuclear antibody class IgG, IgG autoantibodies to AMA-M2 (by immuno-blot), antibodies to cardiolipin and lupus anticoagulant. Due to the fact that in practice the conducting patients RAC no standardized criteria for determining the severity and degree of disease activity, use of prognostic indicators (clinical, laboratory and constitutional parameters) unfavorable course of RAC in dermatology practice would improve the quality of diagnosis. Thus, we have presented clinical studies have shown that early diagnosis of this disease is the determining factor of a favorable prognosis of the disease.

49

Solovyov, S. K., A. A. Mesnyankina, and E. A. Aseeva. "Prospects for anti-BLyS treatment of systemic lupus erythematosus." Medical Council, no. 9 (June 12, 2019): 92–95. http://dx.doi.org/10.21518/2079-701x-2019-9-92-95.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Review of literature on the analysis of current data on the efficacy of belimumab (BLM) in systemic lupus erythematosus (SLE). It provides data on the high efficacy of BLM in high and medium activity of SLE in patients with joints damage, skin lesions and high immunological activity. The paper describes clinical cases of a rituximab and belimumab combination therapy in SLE patients.

50

Kawahara, Kyoko, Tomoyuki Mukai, Masanori Iseki, Akiko Nagasu, Hajime Nagasu, Takahiko Akagi, Shoko Tsuji, et al. "SH3BP2 Deficiency Ameliorates Murine Systemic Lupus Erythematosus." International Journal of Molecular Sciences 22, no. 8 (April 17, 2021): 4169. http://dx.doi.org/10.3390/ijms22084169.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background: The adaptor protein Src homology 3 domain-binding protein 2 (SH3BP2) is widely expressed in immune cells. It controls intracellular signaling pathways. The present study was undertaken to investigate the role of SH3BP2 in a murine systemic lupus erythematosus model. Methods: For the lupus model, we used Faslpr/lpr mice. Clinical and immunological phenotypes were compared between Faslpr/lpr and SH3BP2-deficient Faslpr/lpr mice. Splenomegaly and renal involvement were assessed. Lymphocyte subsets in the spleen were analyzed by flow cytometry. To examine the role of SH3BP2 in specific cells, B cell-specific SH3BP2-deficient lupus mice were analyzed; T cells and bone marrow-derived dendritic cells and macrophages were analyzed in vitro. Results: SH3BP2 deficiency significantly reduced lupus-like phenotypes, presented as splenomegaly, renal involvement, elevated serum anti-dsDNA antibody, and increased splenic B220+CD4−CD8− T cells. Notably, SH3BP2 deficiency in B cells did not rescue the lupus-like phenotypes. Furthermore, SH3BP2 deficiency did not substantially affect the characteristics of T cells and macrophages in vitro. Interestingly, SH3BP2 deficiency suppressed the differentiation of dendritic cells in vitro and reduced the number of dendritic cells in the spleen of the lupus-prone mice. Conclusions: SH3BP2 deficiency ameliorated lupus-like manifestations. Modulating SH3BP2 expression could thus provide a novel therapeutic approach to autoimmune diseases.